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Abstract Cystein-rich protein 61 (CYR61/CCN1) is a com-
ponent of the extracellular matrix, which is produced and
secreted by several cell types including endothelial cells,
fibroblasts and smooth muscle cells. CCN1 has been impli-
cated in leukocyte migration and the inflammatory process,
but it is also involved in cardiovascular development and
carcinogenesis. It exerts its functions through binding to mul-
tiple integrins present in many different cell types. This mul-
tiplicity in function is now known to contribute to the diverse
array of cellular processes it can regulate. The expression of
CCN1 is tightly regulated by cytokines and growth factors.
However, CCN1 can directly modulate cell adhesion and
migratory processes whilst simultaneously regulating the pro-
duction of other cytokines and chemokines through paracrine
and autocrine feedback loops. This complex functionality of
CCN1 has highlighted the pivotal role this molecule can play
in regulating the immunosurveillance process. Furthermore,
CCN1 has now emerged as an important partner when
targeting components of the infectious or chronic inflamma-
tory disease processes such as atherosclerosis or rheumatoid
arthritis. This review will focus on CYR61/CCN1 and its
ability to control the migration of leukocytes, the production
of cytokines and cell proliferation or senescence at the site of
inflammation.
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CCN1/CYR61 Cysteine-rich protein 61
ECM Extracellular matrix
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Introduction
The immune system consists of a heterogeneous cell popula-
tion that shares the ability to rapidly respond to tissue and
organ injury. Research in immunology is mainly focused on
the roles of inflammatory cytokines and chemokines, antigen-
ic and co-stimulation signals or receptors for pathogen-
associated molecular patterns. However, the extracellular ma-
trix (ECM) is emerging as an essential partner modulating the
course of inflammation. Aside from providing a structural
support for cell adhesion, the ECM influences various aspects
of cellular life not only in physiological conditions but also in
pathological conditions [1, 2]. Immune cells infiltrating the
site of inflammation secrete not only cytokines but also pro-
teases, such as matrix metalloproteinases (MMP), which mod-
ify the synthesis of ECM by tissue resident cells or their
cleavage. Consequently, modified ECM can alter cell migra-
tion, activation, differentiation and survival. For example,
cleavage of type I collagen by MMPs enables a chemotactic
activity analogous to CXC-chemokine ligand 8 (CXCL8) on
neutrophils during lung inflammation [3]. ECM compounds
such as fibronectin, heparin sulphate or hyaluronan, have been
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well studied over many years; however, the CCN family of
proteins has not been as well characterised for their role in the
inflammatory response [4].
Named after the first three members, cysteine-rich protein
61 (CYR61; CCN1), connective tissue growth factor (CTGF;
CCN2) and nephroblastoma overexpressed protein (NOV;
CCN3), the CCN family comprises six secreted proteins that
share a similar modular structure consisting of four domains
exhibiting sequence homologies to insulin-like growth factor
binding protein, von Wil lebrand factor type C,
thrombospondin type I and a cysteine knot motif [4, 5].
CCN proteins were initially identified as immediate-early
genes whose secretion was induced by mitogenic factors
[4–6]. More recently, studies revealed that these matricellular
proteins play critical roles in cardiovascular development,
inflammation, injury repair and cancer. Their functionality is
mediated via specific integrin binding and heparin sulphate
proteoglycans, which in turn can activate signalling pathways
responsible for the regulation of cell adhesion, migration,
proliferation or senescence. In addition, CCN binds growth
factors (BMP, TGFβ) or ECM-associated proteins such as
laminin, thus bridging cells and extracellular ligands (Fig. 1)
[4, 5, 7].
In this review, we will focus on CYR61/CCN1 and how it
is implicated in many different pathways of the immune and
inflammatory process.
Expression and regulation of CCN1 under homeostasis
Under homeostatic conditions, matricellular protein CYR61/
CCN1 is expressed at low levels in most adult tissues by
endothelial cells, fibroblasts and vascular smooth muscle cells
(VSMC). In addition, intracellular flow cytometry studies
revealed constitutive expression of CCN1 in human leuko-
cytes circulating in the blood [8]. No expression was reported
in developing murine thymocytes [9]. During embryonic de-
velopment, the importance of CCN1 for the cardiovascular
system has been demonstrated by the phenotype of Ccn1-
deficent mice, which are embryonic lethal because of
cardiovascular defects [10] and deficiencies in promot-
ing angiogenesis [11, 12].
Expression and regulation under pathological conditions
Although expressed at low levels during steady-state
homeostasis, it is remarkable how CCN1 expression is
induced by serum growth factors, cytokines and envi-
ronmental stress.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that principally manifests in the synovial joints.
Overexpression of CCN1 protein has been reported in
fibroblast-like synoviocytes (FLS), with elevated levels ob-
served in synovial fluid samples from RA patients as com-
pared with healthy controls and patients suffering from oste-
oarthritis [13]. Similarly, CCN1 mRNA was strongly in-
creased in lymphoblastoid B cell lines derived from RA-
discordant monozygotic twins [13, 14], being one of the three
most overexpressed genes [14]. Interestingly, mRNA and
protein expression of CCN1 is inhibited by TNFα in
chondrocytes [15–17], whereas it is strongly induced in pri-
mary human osteoblasts and U2OS cells by TNFα, oncostatin
M and the pro-inflammatory cytokines IL6 and IL1β [16, 17].
However, TNFα was shown to have no effect on CCN1
expression in FLS. The expression of CCN1 in FLS is induced
by IL17 in a p38 MAPK and NF-κB-dependent manner and
suppressed by simvastatin treatment [16–19]. These findings
strongly suggest that CCN1 plays a key role in inflammation
and chronic inflammatory disease.
Bacterial and viral infection
Lysophosphatidic acid (LPA) is a bioactive lysophospholipid
that can bind to specific G protein-coupled receptors termed
LPA receptors. These interactions have been shown promote
morphological changes and cell proliferation/survival.
Production of LPA is a common feature of many bacteria. In
vitro infection of primary murine epithelial cells or a human
epithelial cell line with the Gram-negative bacteria Yersinia
enterocolitica led to increased mRNA expression of CCN1
through the activation of LPA receptors [20, 21]. Similar
results have also been obtained using Gram-negative bacteria
Fig. 1 Schematic representation of CCNs. CCNs share a modular struc-
ture consisting of four domains exhibiting sequence homologies to insu-
lin-like growth factor binding protein (IGFBP), von Willebrand factor
type C (vWF), thrombospondin type I (TSP) and a cysteine knot motif
(CK). They bridge cells to ECM compounds by binding cell surface
integrins and heparin sulphate proteoglycans (HSPG)
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Escherichia coli and Pseudomonas aeruginosa and Gram-
positive bacteria Enterococcus faecalis or Staphylococcus
aureus [21]. Induction of CCN1 protein has also been shown
to occur in primary murine hepatocytes stimulated with LPS
in vitro through the TLR4/MyD88/AP-1 pathway and hepa-
tocytes of LPS-stimulated normal and obese mice [22].
Consistent with these observations, increased levels of
CCN1 have been reported in the blood of patients with sepsis,
compared to healthy controls [8].
Comparably, in vitro infection of human epithelial
cell lines with poliovirus, hepatitis C virus [23] and
coxsackievirus B3 [24] or in vivo with oncolytic HSV-
1 in rats [25] also led to upregulation of CCN1 expres-
sion in epithelial cells. The induction of CCN1 follow-
ing coxsackievirus B3 infection occurs through the ac-
tivation of JNK, which was induced by virus replication
and viral protein expression in infected epithelial cells
[24]. Interestingly, inhibition of CCN1 expression with
shRNA reduces coxsackievirus B3 growth [24] whilst
CCN1 treatment reduced HSV-1-derived oncolytic virus
replication and cytotoxicity [26].
These studies have strongly highlighted the induction of
CCN1 as a common host response to bacterial or viral
infection.
Vascular injury
Protein and mRNA levels of CCN1 are increased in the
plasma of patients with giant cell myocarditis [8] and cardiac
biopsies of patients with dilated cardiomyopathy, respectively
[27]. This was also observed in a mouse model of myocardial
infarction [28] and diabetic retinopathy [29]. In the context of
diabetic retinopathy, CCN1 is processed by MMP2 and
MMP14 [30–32], where different domains are observed to
exhibit proangiogenic or antiangiogenic activities [32]. The
expression of CCN1 was upregulated in arterial smooth mus-
cle walls during restenosis following balloon angioplasty in
rat carotid artery, as part of ECM remodelling resulting from
vascular injury [33]. Furthermore, CCN1 was shown to be
highly expressed, via angiotensin 2, in aortic arteriosclerotic
plaques of ApoE-deficient mice and in human arteriosclerotic
lesions [34–37].
Colon inflammation
A role for angiogenesis and angiogenic factors is established
in inflammatory bowel diseases. In this context, increased
levels of CCN1 were measured in the colons of patients with
Crohn's disease and ulcerative colitis and in colons of mice
treated with dextran sodium sulphate to induce inflammatory
colitis [38].
Receptors of CCN1
Matricellular CCN1 has the ability to mediate cell adhe-
sion, mainly through binding specific integrins although it
does not contain the canonical RGD sequence (Fig. 1 and
Table 1). This has been reported not only for human T
cells, B cells, natural killer (NK) cells or monocytes in the
blood [8, 34, 37, 39] but also for CD34+ circulating
progenitors and platelets [40, 41]. Some discrepancies
have been observed between human and mouse cells.
Hence, in mouse, CCN1 binds to CD11b+ cells and B
cells but not T cells or NK cells [39]. Regarding CD34+
progenitors, interactions occur through αMβ2 and αVβ3
[40]. Interactions with monocytes and macrophages are
mediated by integrin αMβ2, αDβ2 and syndecan-4 [22,
34, 37, 42, 43], whilst integrin α6β1 and αLβ2 are
important for thymocytes [9]. For mesenchymal cell pop-
ulations, integrins αVβ5, α6β1 and syndecan-4 support
CCN1 binding to fibroblasts [44, 45] whilst heparan sul-
phate proteoglycans and integrin α6β1 are implicated for
vascular smooth muscle cells [33, 46, 47] and only
integrin α6β1 for thymic epithelial cells [9].
Table 1 Receptors of CCN1
Cell type Species Receptors References
B cells Human Unknown [8, 34, 37, 39]
T cells
NK cells
T cells Mouse No binding [39]
NK cells
Spleen dendritic cells
CD34+ circulating
progenitors
Human Integrin αMβ2 [40]
Integrin αVβ3
Monocyte Human Integrin αMβ2 [22, 34, 37, 42, 43]
Macrophage Mouse Integrin αDβ2
Syndecan-4
Osteoblast Human Integrin αVβ3 [61–63]
Osteoclast Mouse Integrin αVβ5
Spleen CD11b+ cells Mouse Unknown [39]
Thymocytes Mouse Integrin α6β1 [9]
Integrin αLβ2
Thymic
epithelial cells
Mouse Integrin α6β1 [9]
Platelets Human Integrin αIIbβ3 [41]
Fibroblasts Human Integrin αVβ5 [44, 45]
(including FLS) Mouse Integrin α6β1
Syndecan-4
Vascular smooth
muscle cells
Human Heparan sulphate
proteoglycan
[33, 46, 47]
Mouse Integrin α6β1
Rat
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Role of CCN1 in cytokine production
In diabetic retinopathy, many defects are associated with
localised inflammation. The upregulation of CCN1 leads to
increased expression of MCP-1 in chorioretinal vascular en-
dothelial cells through the αVβ3/PI3K/Akt signalling path-
way [48]. In the same way, CCN1 treatment stimulates the
production of IL6 in FLS of RA patients via the αvβ5
integrin/Akt/NF-κB pathway [18], promoting Th17 cell dif-
ferentiation in vitro. Interestingly, targeting CCN1 with
blocking antibodies has been shown to reduce IL6 levels
and a Th17 response in a collagen-induced arthritis model of
RA [18]. In addition, CCN1 has been observed to be increased
in the synovial fluid of RA patients, which is known to
promote the proliferation and survival of FLS [13]. CCN1
also promotes CCL2 expression in osteoblasts [16], skin
fibroblasts [49] and renal tubular epithelial cell [50]. In murine
macrophages, treatment with CCN1 induced transcriptional
changes characteristic of M1 macrophages, including the up-
regulation of TNFα, IL1α, IL1β, IL6, IL12b, MIP1α, MCP3
and IP10 in an NF-κB-dependent manner [42]. In summary,
these studies have shown that CCN1 plays a diverse role in
promoting cytokine production and may be a key player in the
inflammatory response and chronic disease.
Role of CCN1 in adhesion and migration
CCN1 supports the adhesion of a variety of cell types includ-
ing monocytes [34, 37], macrophages [42], developing thy-
mocytes and thymic epithelial cells [9], human blood leuko-
cytes [8], fibroblasts [45, 51], vascular smooth muscle cells
[52] or endothelial cells [53].
As well as mediating cell adhesion to multiple cell types,
CCN1 has the ability to promote cell migration events of
endothelial cells [32, 38, 53, 54], cancer cells [5, 55, 56] and
vascular smooth muscle cells [33]. CCN1 acts as a
chemoattractant for lymphocytes, monocytes and murine
macrophages in multiple in vitro studies [8, 22, 39].
Consistent with these observations, CCN1 had no effect on
integrin density or chemokine receptor expression in human
monocyte and lymphocyte populations [8]. It activates the
PI3K/Akt and p38 signalling pathways and actin polymerisa-
tion [8] while murine macrophage chemotaxis occurs via
MEK/ERK signalling [22]. A role for CCN1 in disease has
been confirmed in numerous animal studies, CCN1 protein
treatment or overexpression in the liver exacerbates hepatic
inflammation and macrophage infiltration in high-fat diet
mice compared to normal fed mice [22]. Similarly, the impor-
tance of CCN1 in kidney fibrosis was demonstrated in a
model of unilateral ureteral obstruction surgery in mice [50].
In this model, treatment with anti-CCN1 antibodies reduced
kidney fibrosis by decreasing macrophage infiltration [50].
Finally, simvastatin treatment inhibits CCN1 expression and
CCN1-dependent infiltration of macrophages and CCN1+
osteoblasts and slows down the progression of disease in the
mouse model of collagen-induced arthritis [16, 17, 19].
The chemotactic activity of CCN1, secreted by vascular
endothelial growth factor (VEGF)-stimulated osteoblasts, reg-
ulates the formation of capillary-like sprouts by endothelial
cells in vitro and promotes angiogenic processes in vivo [54].
CCN1 attracts endothelial cells and promotes angiogenesis in
the context of bone fracture in mouse models, thereby con-
tributing to the fracture healing process [54]. In addition,
CCN1 promotes the recruitment and the differentiation of
circulating CD34+ progenitors to endothelial cells, hinting at
a role in cardiovascular regeneration [40].
Consistent with observations using chemokines, prolonged
exposure to CCN1 inhibits the migration of spleen macro-
phages, T cells and monocytes [8, 39]. Actually CCN1 abol-
ishes their chemotactic response to CCL2 or SDF1 [8, 39] by
downregulating PI3K, p38 and Akt signalling [8]. A regula-
tory role for CCN1 in immune cell migration was also dem-
onstrated in inflammatory cardiomyopathy. In experimental
autoimmune myocarditis, systemic CCN1 overexpression in-
hibits the migration of circulating immune cells, without af-
fecting cardiac chemokine or chemokine receptor expression
thereby ameliorating the disease process and reducing disease
scores [39].
Role of CCN1 in cell proliferation and survival
Vascular endothelium
CCN1 promotes cell survival and tubule formation in human
umbilical vein endothelial cells. Interestingly, proliferation
can be mediated through the integrin α6β1 in the unactivated
state, whereas VEGF stimulation is required to activate the
integrinαVβ3 for proliferation and adhesion/migrationmech-
anisms of endothelial cells [53]. A truncated form of CCN1
consisting of the insulin-like growth factor binding protein
and von Willebrand factor type C domains has been shown to
exhibit proangiogenic properties on retinal endothelial cells,
whilst the presence of the thrombospondin type I domain to
the previous variant suppressed cell growth [32].
As mentioned above, CCN1 can regulate the recruitment
and differentiation of CD34+ progenitor cells, which are im-
portant in cardiovascular tissue regeneration [40].
Furthermore, treatment with CCN1 or supernatants from
CCN1-stimulated human CD34+ cells has been shown to
promote the proliferation of endothelial cells and enhance
endothelial proliferation and neovascularization [40].
VSMC proliferation is characteristic of many vascular
diseases, such as atherosclerosis. Forced expression of
FOXO3a in VSMC decreased their viability through
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inhibition of CCN1 in a rat balloon carotid arterial injury
model [52].
Rheumatoid arthritis
In addition to sustaining a Th17 response in RA [18], the high
levels of CCN1 detected in synovial fluid and tissue are
responsible for the proliferation of FLS in RA patients.
Moreover, CCN1 also protects FLS from apoptosis by main-
taining Bcl-2 expression in FLS [13].
Thymic epithelial cells and thymus function
In the thymus, not only thymocytes are undergoing massive
proliferation but also thymic epithelial cells (TEC) too. TEC
are the main stromal cell populations of the thymic microen-
vironment that provide key signals to developing thymocytes.
Alteration in TEC architecture is characteristic of age-
associated thymic involution or cytoablative treatments [57,
58]. In vitro, CCN1 treatment of foetal thymic lobes favours
the expansion of thymic stroma by promoting the proliferation
of TEC through integrin α6β1/Akt axis. In vivo, the overex-
pression of CCN1 in thymic stroma increases the production
of T cells via expansion of the TEC compartment. Thereby
additional space is available for the recruitment and hosting of
circulating hematopoietic progenitors and their development
into T cells [9]. It is important to mention that CCN1 does not
affect the proliferation and development of thymocytes per se.
Role of CCN1 in cell death and senescence
In total opposition to its proliferative activities, CCN1 can also
contribute to senescence or cell death induction, which has
been evidenced in several models.
In TNFα-resistant primary human fibroblasts, CCN1 un-
masks the cytotoxic activity of TNFα. In this way, mice
expressing a mutant Ccn1 are resistant to TNFα-induced
apoptosis in vivo [44]. During the healing process of cutane-
ous wounds, senescent fibroblasts accumulated in granulation
tissues, where CCN1 was strongly expressed [49]. CCN1
induced the expression of antifibrotic genes in fibroblasts,
thus limiting fibrosis during tissue repair. Induction of senes-
cence by CCN1 occurred through binding to integrin α6β1
and heparan sulphate proteoglycans, activating p53 and
Rac1/Nox1 signalling. As a consequence, mice bearing a
mutant Ccn1 gene exhibited an exacerbated fibrosis [45].
Comparably, treatment of muscle progenitor cells with
CCN1 hampered their proliferative potential through the in-
crease of p53 and p16Ink4A levels but without affecting the
myogenic marker myoD [59].
Fibrosis is also observed in liver injuries. Upon carbon
tetrachloride intoxication or bile duct ligation, CCN1 was
induced, promoting senescence of hepatic stellate cells and
portal fibroblasts [60]. In this model, integrin α6β1 and the
Rac1/Nox1 pathway also played a regulatory role [60], as
described in cutaneous wound healing [45]. Consequently,
mice with hepatocyte-specific Ccn1-deletion displayed aggra-
vated fibrosis due to a lack of cellular senescence [60].
Conclusion
The molecule CCN1 can exhibit diverse and different func-
tions based on its modular structure and its ability to bind
different integrins, thereby implicating it in distinct and com-
plex processes. It is therefore remarkable that CCN1 expres-
sion is induced by proinflammatory cytokines while promot-
ing itself the production of cytokines and chemokines.
Additionally, locally produced CCN1 supports immune cell
trafficking not only by both attracting and immobilising im-
mune cells but also by driving differentiation by turning
macrophages into M1-type cells. However, despite its upreg-
ulation upon viral or bacterial infections, the multiple roles of
CCN1 have not been investigated in detail for these condi-
tions. Finally, the expression of CCN1 in thymic stromal cells
and its ability to improve thymus size arise interesting per-
spectives for studies in lymph nodes and bone marrow, two
immune organs, which share structural similarities with the
thymus and the setup of an appropriate immune response.
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